Empiric antifungal therapy for the neutropenic patient.
One of the major challenges facing oncologists today is invasive fungal infection. Difficult to diagnose and deadly when missed, invasive fungal infection--primarily by Candida and Aspergillus organisms--is the major infectious cause of death associated with chemotherapy-induced myelosuppression. In this review, the problem will be described and evidence-based approaches to management, including assessment for risk factors and empiric antifungal therapy, will be discussed. Finally, the future of diagnostic and therapeutic strategies for protecting the immunocompromised patient will be considered.
Wingard
J R
JR
Bone Marrow Transplant Program, University of Florida College of Medicine, USA. wingajr@medicine.ufl.edu
Leather
H L
HL
D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy*; D002177:Candidiasis / Q000188:drug therapy*; D006801:Humans; D009503:Neutropenia / Q000150:complications*
D000935:Antifungal Agents